Panacea Acquisition announced that its registration statement for the proposed business combination with Nuvation Bio has been declared effective by the SEC. A shareholder vote on the merger is set for Feb. 9.
In addition to the approximately $144 million held in Panacea’s trust (assuming no redemptions), a group of healthcare investors has committed to participate in concurrent equity financings totaling slightly more than $500 million at $10 per share.
Nuvation Bio is focused on developing cancer treatments. Read more.
